The Marketing of5-Hydroxytryptamine: Depression or Anxiety?
- 1 June 1991
- journal article
- review article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 158 (6) , 737-742
- https://doi.org/10.1192/bjp.158.6.737
Abstract
The discovery that tricyclic antidepressants blocked the re-uptake of both noradrenaline and 5-hydroxytryptamine (5-HT) was a significant step on the road to the development of the monoamine hypotheses of depression (Healy, 1987). The subsequent demonstration that the de-aminated metabolites of amitriptyline and imipramine, nortriptyline and desipramine, were antidepressants tilted the balance toward noradrenaline as the pertinent neurotransmitter, as these latter drugs were clearly inhibitors of noradrenergic rather than 5-HT uptake.Keywords
This publication has 36 references indexed in Scilit:
- Relapse in chronic depressives on withdrawal of L-tryptophanThe Lancet, 1990
- The prehistory of psychotherapeutic agentsJournal of Psychopharmacology, 1990
- Artistic imagination and the discovery of antidepressantsJournal of Psychopharmacology, 1990
- Monoamine Oxidase Inhibitors in Depression: History and MythologyJournal of Psychopharmacology, 1990
- The benefits and risks of antidepressant drugsHuman Psychopharmacology: Clinical and Experimental, 1988
- Biochemical Aspects of Therapy-Resistant DepressionThe British Journal of Psychiatry, 1988
- 5-Hydroxytryptamine Receptor SubtypesAnnual Review of Neuroscience, 1988
- Clomipramine, Tryptophan and Lithium in Combination for Resistant Endogenous Depression: Seven Case StudiesThe British Journal of Psychiatry, 1987
- The Newcastle Chronic Depression Study: Results of a Treatment RegimeInternational Clinical Psychopharmacology, 1987
- THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A double‐blind, multicenter trialActa Psychiatrica Scandinavica, 1974